| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Research and development | $3.0M-12.2% | $3.5M-39.2% | $5.7M+37.6% | $4.2M+261.7% | $1.1M+117.7% | $527K |
| General and administrative | $3.9M+5.9% | $3.7M-14.5% | $4.3M-9.4% | $4.8M+165.7% | $1.8M+200.7% | $596K |
| Sales and marketing | $8K | — | $283K-37.2% | $451K+55.8% | $290K+296.8% | $73K |
| Total operating expenses | $7.0M-3.0% | $7.2M-30.5% | $10.3M+10.1% | $9.4M+190.0% | $3.2M+170.0% | $1.2M |
| Operating loss | -$7.0M+3.0% | -$7.2M+30.5% | -$10.3M-10.7% | -$9.3M-188.5% | -$3.2M-170.0% | -$1.2M |
| Interest expense | -$839+99.9% | -$823K | — | — | — | — |
| Interest income | $98K-33.1% | $146K-11.6% | $165K+83.9% | $90K | — | — |
| Other income, net | $8K-94.0% | $129K-32.9% | $192K+14.2% | $168K+390.8% | $34K | — |
| Total other income (expense), net | $104K+119.1% | -$548K-253.4% | $357K+1615.6% | $21K+108.1% | -$258K-777.4% | $38K |
| Net loss | -$6.8M+11.3% | -$7.7M+22.5% | -$10.0M-7.1% | -$9.3M-166.5% | -$3.5M-201.2% | -$1.2M |
| Deemed dividend on warrant modification | $13.2M | — | — | — | — | — |
| Net loss applicable to common stockholders | -$6.8M+67.3% | -$20.9M-110.4% | -$10.0M | — | — | — |
| Net Loss per share to common stockholders – Basic (in Dollars per share) | -$15.25+96.7% | -$456.75+87.4% | -$3631.48-39287.0% | -$9.22-2148.8% | -$0.41 | — |
| Net Loss per share to common stockholders – Diluted (in Dollars per share) | -$15.25+96.7% | -$456.75+87.4% | -$3631.48 | — | — | — |
| Weighted average common shares outstanding – Basic (in Shares) | 449K+879.4% | 46K+1572.7% | 3K-99.7% | 1.0M-88.2% | 8.5M | — |
| Weighted average common shares outstanding – Diluted (in Shares) | 449K+879.4% | 46K+1572.7% | 3K | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.